Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Centogene NV CNTGF

Healthcare
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's... see more

Recent & Breaking News (OTCQB:CNTGF)

CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence - Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO

GlobeNewswire December 20, 2021

CENTOGENE Reports Third Quarter 2021 Financial Results

GlobeNewswire November 24, 2021

CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

GlobeNewswire November 18, 2021

CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

GlobeNewswire November 4, 2021

CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study

GlobeNewswire October 28, 2021

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

GlobeNewswire October 6, 2021

CENTOGENE's Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects

GlobeNewswire September 29, 2021

CENTOGENE Reports Second Quarter 2021 Financial Results

GlobeNewswire September 7, 2021

CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021

GlobeNewswire September 1, 2021

CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development

GlobeNewswire July 27, 2021

CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting

GlobeNewswire June 25, 2021

CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years

GlobeNewswire June 22, 2021

CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event

GlobeNewswire June 16, 2021

CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021

GlobeNewswire June 9, 2021

CENTOGENE Announces Virtual Investor Event

GlobeNewswire June 7, 2021

CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

GlobeNewswire June 2, 2021

CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution

GlobeNewswire June 1, 2021

CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer

GlobeNewswire May 26, 2021

CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals

GlobeNewswire May 18, 2021

CENTOGENE Extends Global Parkinson's Disease Study

GlobeNewswire May 10, 2021